Mintz Life Sciences Deal Activity (July – September 2020)
Mergers & Acquisitions
- Represented QIAGEN N.V., a Germany-based provider of life science and molecular diagnostic solutions, in its $248M cross-border acquisition of NeuMoDx Molecular, Inc., a US-based company that designs and develops molecular diagnostic solutions for hospital and clinical reference laboratories (September 2020)
- Represented a Germany-based life sciences company in its investment in a US-based life sciences company that is a core supplier in the fight against COVID-19 (September 2020)
- Represented Philips in its acquisition of Intact Vascular, Inc., a developer of medical devices for minimally-invasive peripheral vascular procedures (September 2020)
- Represented Lodo Therapeutics Corp., a biotechnology company reinventing natural product drug discovery by applying its informatics-enabled technology platform to previously undruggable disease targets, in its acquisition of Conifer Point Pharmaceuticals, LLC (August 2020)
Venture Capital
- Represented Finch Therapeutics Group, Inc. in its $90M Series D financing led by OMX Ventures (September 2020)
- Represented Fulgent Genetics, Inc. in its Series A investment in BostonMolecules Inc. (September 2020)
- Represented FASCinate Therapeutics in a $15M Series A Preferred Stock financing led by Kainos Medicine (August 2020)
- Represented Partner Fund Management in its Series B investment in Erasca, Inc. (August 2020)
- Represented Cowen Healthcare Investments in its Series G investment in F2G Ltd. (July 2020)
- Represented Matrix Capital Management in its $25M investment in VelosBio Inc. (July 2020)
- Represented Vicarious Surgical in its Series A3 financing (July 2020)
Licensing & Collaborations
- Represented Innovent Biologics, Inc. in a global expansion of their strategic alliance with Eli Lilly and Company for TYVYT® (sintilimab injection), an anti-PD-1 monoclonal antibody immuno-oncology medicine that was co-developed by Innovent and Lilly in China (August 2020)
- Represented BlinkBio in out-licensing its patent rights to OS Therapies, a late-stage clinical research biotechnology company focused on Osteosarcoma and other solid tumors (August 2020)
- Represented BlinkBio in out-licensing its patent rights to ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors (August 2020)
Capital Markets
Represented the issuer:
- Represented Fulgent Genetics in its $125M at-the-market offering underwritten by Piper Jaffray (September 2020)
- Represented Wave Life Sciences Ltd. in its $100M public offering underwritten by Jefferies LLC, SVB Leerink LLC, and Mizuho Securities USA LLC (September 2020)
- Represented NuCana plc in its $80M public offering underwritten by Citigroup, Jefferies LLC, Cowen and Company, William Blair, and Truist Securities (September 2020)
- Represented Intra-Cellular Therapies in its $380M public offering underwritten by J.P. Morgan, Goldman Sachs, SVB Leerink, Evercore, Cantor Fitzgerald, and Canaccord Genuity (September 2020)
- Represented Spero Therapeutics in its $80M public offering underwritten by Cowen and Company, Evercore, and Cantor Fitzgerald (September 2020)
- Represented Albireo Pharma, Inc. in its $160M public offering underwritten by William Blair & Company, L.L.C. and Cowen and Company, LLC (September 2020)
- Represented Yield10 Bioscience, Inc. in its $3.5M public offering underwritten by Maxim Group, LLC (September 2020)
- Represented Inhibrx, Inc. in its $136.9M initial public offering (IPO) underwritten by Jefferies LLC, Credit Suisse Securities, and Evercore Group (August 2020)
- Represented Quanterix Corporation in its $91M public offering underwritten by Cowen and Company, LLC, Canaccord Genuity LLC, SVB Leerink LLC (August 2020)
- Represented SELLAS Life Sciences Group, Inc. in its $9.2M private placement with Maxim Group LLC acting as placement Agent (July 2020)
Represented the underwriters:
- Represented the underwriters in the $10M public offering of Adamis Pharmaceuticals Corporation underwritten by Raymond James & Associates, Inc. and Maxim Group, LLC (September 2020)
- Represented the underwriters in the $50M public offering of Trevena, Inc. underwritten by Guggenheim Securities (August 2020)
- Represented the underwriters in the $188.5M public offering of Adverum Biotechnologies, Inc. underwritten by SVB Leerink LLC, Goldman Sachs & Co. LLC, Piper Sandler & Co., and Cowen and Company, LLC (August 2020)
- Represented the underwriters in the $16.5M public offering of PDS Biotechnology Corporation underwritten by Oppenheimer & Co. Inc. (August 2020)
- Represented the underwriters in the $23M public offering of DiaMedica Therapeutics Inc. underwritten by Guggenheim Securities (August 2020)
- Represented the underwriters in the $38M public offering of CASI Pharmaceuticals, Inc. underwritten by Oppenheimer & Co. Inc. (July 2020)
- Represented the underwriters in the $492M public offering of Acceleron Pharma Inc. underwritten by JP Morgan Securities, SVB Leerink, Cowen and Company, Barclays, Credit Suisse, and Piper Sandler (July 2020)
Represented the sales agent / placement agent:
- Represented the placement agent in the $17M registered direct offering of Conformis Inc. with Oppenheimer & Co. Inc. as placement agent (September 2020)
- Represented the sales agent in a $30M at-the-market offering of Forte Biosciences, Inc. with Ladenburg Thalmann & Co. acting as sales agent (September 2020)
- Represented the placement agent in the $65M directed issue of shares of Saniona AB to U.S. and international institutional investors, with Oppenheimer & Co. Inc. as placement agent (August 2020)
- Represented the sales agent in a $40M at-the-market offering of Bionano Genomics, Inc. with Ladenburg Thalmann & Co. acting as sales agent (August 2020)
- Represented the placement agent in the $7.5M public offering of Tonix Pharmaceuticals Holding Corp. with Alliance Global Partners as placement agent (July 2020)
View Deal Activity from April – June 2020
View Deal Activity from October – December 2020
View Deal Activity from January – March 2021